MDxHealth SA (NASDAQ:MDXH) Sees Significant Decrease in Short Interest

MDxHealth SA (NASDAQ:MDXH) saw a large decrease in short interest during the month of February. As of February 13th, there was short interest totaling 22,470 shares, a decrease of 23.1% from the January 29th total of 29,229 shares. Based on an average trading volume of 96,543 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.0% of the shares of the stock are short sold. Currently, 0.0% of the shares of the stock are short sold. Based on an average trading volume of 96,543 shares, the days-to-cover ratio is currently 0.2 days.

Analyst Ratings Changes

Several equities analysts recently weighed in on MDXH shares. TD Cowen raised their price objective on shares of MDxHealth from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. BTIG Research reiterated a “buy” rating and issued a $7.00 price objective on shares of MDxHealth in a report on Tuesday, December 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of MDxHealth in a report on Monday, December 29th. Finally, Lake Street Capital upped their price target on MDxHealth from $7.00 to $9.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, MDxHealth has a consensus rating of “Moderate Buy” and a consensus target price of $7.75.

Hedge Funds Weigh In On MDxHealth

A number of institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd increased its position in MDxHealth by 220.0% during the fourth quarter. XTX Topco Ltd now owns 40,860 shares of the company’s stock worth $146,000 after buying an additional 28,090 shares during the last quarter. Millennium Management LLC boosted its position in shares of MDxHealth by 328.3% in the fourth quarter. Millennium Management LLC now owns 116,831 shares of the company’s stock valued at $417,000 after acquiring an additional 89,553 shares during the period. Balyasny Asset Management L.P. bought a new stake in MDxHealth in the 4th quarter valued at about $68,000. 683 Capital Management LLC acquired a new stake in MDxHealth during the fourth quarter worth approximately $384,000. Finally, Lazard Asset Management LLC acquired a new stake in shares of MDxHealth during the 4th quarter worth $83,000.

MDxHealth Trading Up 0.9%

MDXH stock traded up $0.03 during trading on Monday, hitting $3.43. 82,435 shares of the stock traded hands, compared to its average volume of 130,502. The stock has a market cap of $169.79 million, a price-to-earnings ratio of -5.12 and a beta of 1.61. MDxHealth has a one year low of $1.35 and a one year high of $5.33. The company has a 50 day simple moving average of $3.55 and a 200 day simple moving average of $3.77.

MDxHealth (NASDAQ:MDXH) last released its earnings results on Thursday, February 26th. The company reported $999.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $999.13. MDxHealth had a negative net margin of 31.07% and a negative return on equity of 1,078.01%. The company had revenue of $29.55 million for the quarter, compared to the consensus estimate of $26.05 million. As a group, analysts predict that MDxHealth will post -1.15 earnings per share for the current fiscal year.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.